Related Experiment Video
Updated: Sep 22, 2026

A Surgical Approach for Optic Nerve Crush in a Rabbit Model
Published on: July 8, 2025
Prophylactic ondansetron in prevention of postoperative nausea and vomiting following pediatric strabismus surgery: a
S Sadhasivam1, D Shende, R Madan
1Department of Anesthesiology and Dr. Rajendra Prasad Center for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi.
Insights
A 75 microg/kg dose of ondansetron effectively prevents postoperative nausea and vomiting (PONV) in children undergoing strabismus repair. This dosage is as effective as higher doses, improving outcomes and parental satisfaction.
Area of Science:
- Anesthesiology
- Pediatric Surgery
- Pharmacology
Background:
- Postoperative nausea and vomiting (PONV) is a common complication in pediatric patients.
- Strabismus repair surgery in children presents a specific risk for PONV.
- Evaluating prophylactic antiemetic strategies is crucial for improving pediatric surgical outcomes.
Purpose of the Study:
- To assess the antiemetic effectiveness of prophylactic ondansetron in pediatric patients undergoing strabismus repair.
- To determine the optimal dose-response relationship for ondansetron in preventing PONV.
- To evaluate the clinical usefulness and impact on patient outcomes of ondansetron prophylaxis.
Main Methods:
- A randomized controlled trial involving 180 pediatric patients (2-12 years) undergoing strabismus repair.
- Patients received placebo or intravenous ondansetron at doses of 25, 50, 75, 100, or 150 microg/kg.
- PONV incidence, duration of postanesthesia care unit stay, and parental satisfaction were recorded over 24 hours.
Main Results:
- Ondansetron significantly reduced PONV incidence at doses of 75, 100, and 150 microg/kg compared to placebo.
- Shorter postanesthesia care unit stays and improved parental satisfaction were observed with 75, 100, and 150 microg/kg ondansetron.
- The 75 microg/kg dose demonstrated equivalent efficacy and benefits to the 150 microg/kg dose.
Conclusions:
- Prophylactic ondansetron at 75 microg/kg is an effective and clinically useful dose for preventing PONV in pediatric strabismus surgery.
- This dose provides comparable benefits to higher doses, optimizing antiemetic therapy.
- Routine use of 75 microg/kg ondansetron can improve perioperative outcomes in pediatric patients.
Background:
This study evaluated the antiemetic effectiveness, dose-response, and clinical usefulness of prophylactic ondansetron in the prevention of postoperative nausea and vomiting (PONV) in children undergoing strabismus repair.
Method:
The authors observed 180 children, American Society of Anesthesiologists physical status I or II, 2-12 yr of age, who were undergoing strabismus repair. After induction of anesthesia with halothane and nitrous oxide in oxygen or intravenous thiopental, children received either placebo (saline) or intravenous ondansetron in doses of 25, 50, 75, 100, and 150 /microg/kg (n = 30). The trachea was intubated and ventilation was controlled. Perioperative analgesic and fluid requirements were standardized. Episodes of nausea and vomiting were recorded for the first 24 h postoperatively. Data such as nonsurrogate (parental satisfaction scores and duration of postanesthesia care unit stay) and therapeutic (numbers needed to prevent and harm) outcome measures were collected.
Results:
The incidences of PONV in the placebo and 25-, 50-, 75-, 100-, and 150-,microg/kg ondansetron groups were 83, 77, 47, 30, 30, and 27%, respectively. The incidence was less in the 75(P = 0.002), 100- (P = 0.002), and 150-microg/kg (P < 0.001) ondansetron groups compared with placebo. Duration of stay in the postanesthesia care unit was shorter in the 75-, 100-, and 150-microg/kg ondansetron groups (P < 0.002) compared with the placebo group. Parental assessment scores for the child's perioperative experience and the positive number needed to prevent PONV were also better and favorable in the 75-, 100-, and 150-microg/kg ondansetron groups compared with the placebo group. The incidence (P > 0.99) and severity (P = 0.63) of PONV were similar in the 75- and 150-microg/kg ondansetron groups. Surrogate, nonsurrogate, and therapeutic outcome measures revealed that 75 microg/kg ondansetron provided the same benefits as did 100 and 150 microg/kg.
Conclusion:
The routine prophylactic use of ondansetron at a dose of 75 microg/kg is as effective as 150 microg/kg in preventing PONV and improving the "true" outcome measures after strabismus repair in children.
Related Concept Videos
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
Phenothiazines, such as prochlorperazine...
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
Two synthetic agonists of THC,...
Drug Dosing: Infants and Children
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption